[CBAY] CymaBay Therapeutics Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 39.37 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.79 Change: 0.01 (0.56%)

chart CBAY

Refresh chart

Strongest Trends Summary For CBAY

CBAY is in the long-term up 942% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: There is no Profile data available for CBAY.

Fundamental Ratios
Shares Outstanding22.37 M EPS-1.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-4.74
P/E To EPS Growth P/S P/BV2.16 Price/Cash Per Share1.2
Price/Free Cash Flow ROA-69.63% ROE-132.38% ROI-114.8%
Current Ratio2.52 Quick Ratio Long Term Debt/Equity0.13 Debt Ratio0.75
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.32 M Cash From Investing Activities1.1 M Cash From Operating Activities-6.16 M Gross Profit
Net Profit-2.33 M Operating Profit-6.78 M Total Assets34.73 M Total Current Assets34.49 M
Total Current Liabilities13.66 M Total Debt4.19 M Total Liabilities16.46 M Total Revenue
Technical Data
High 52 week15.16 Low 52 week5.95 Last close13.03 Last change-4.4%
RSI57.47 Average true range0.49 Beta0.98 Volume47.44 K
Simple moving average 20 days5.53% Simple moving average 50 days3.34% Simple moving average 200 days9.52%
Performance Data
Performance Week4.66% Performance Month17.39% Performance Quart4.07% Performance Half-9.26%
Performance Year110.16% Performance Year-to-date41.63% Volatility daily2.36% Volatility weekly5.27%
Volatility monthly10.8% Volatility yearly37.41% Relative Volume216.06% Average Volume777.64 K
New High New Low

News

2019-03-12 08:00:00 | CymaBay Therapeutics to Present at Upcoming Investor Conferences in March

2019-03-11 16:05:00 | CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

2019-03-06 08:00:00 | CymaBay Announces Pricing of Public Offering of Common Stock

2019-03-05 16:01:00 | CymaBay Announces Proposed Public Offering of Common Stock

2019-03-01 06:59:49 | Edited Transcript of CBAY earnings conference call or presentation 28-Feb-19 9:30pm GMT

2019-02-28 23:24:56 | CymaBay Therapeutics Inc CBAY Q4 2018 Earnings Conference Call Transcript

2019-02-28 16:05:00 | CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update

2019-02-22 07:40:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries — New Research Emphasizes Economic Growth

2019-02-21 08:00:00 | CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28

2019-02-20 08:00:00 | CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-19 08:00:00 | CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

2019-02-15 08:00:00 | CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis

2019-02-07 09:20:58 | CymaBay Therapeutics, Inc. NASDAQ:CBAY: What Does Its Beta Value Mean For Your Portfolio?

2019-01-02 08:00:00 | CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-21 09:29:22 | Have Insiders Been Buying CymaBay Therapeutics, Inc. NASDAQ:CBAY Shares?

2018-12-12 00:10:39 | Hedge Funds Are Buying CymaBay Therapeutics Inc CBAY

2018-11-27 08:25:00 | Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and Upcoming Developments

2018-11-20 08:00:00 | CymaBay Therapeutics to Participate in Upcoming Investor Conferences

2018-11-13 08:00:00 | CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018

2018-11-06 21:14:55 | Edited Transcript of CBAY earnings conference call or presentation 6-Nov-18 9:30pm GMT

2018-11-06 16:10:00 | CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update

2018-10-30 16:05:00 | CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6

2018-10-30 08:00:00 | CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study ENHANCE for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates

2018-10-22 11:57:58 | Weekly CEO Buys Highlight

2018-10-10 07:40:00 | Report: Developing Opportunities within Brunswick, Pebblebrook Hotel Trust, Avaya, Braskem S.A, CymaBay Therapeutics, and The Blackstone Group — Future Expectations, Projections Moving into 2018

2018-10-03 09:00:00 | CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting®

2018-09-24 08:00:00 | CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October

2018-09-17 15:40:38 | Oppenheimer’s 7 Top Stock Picks for September

2018-08-28 10:50:49 | Oppenheimer’s 7 Top Stock Picks for September

2018-08-24 19:55:49 | Edited Transcript of CBAY earnings conference call or presentation 9-Aug-18 8:30pm GMT

2018-08-14 08:00:00 | CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September

2018-08-09 16:01:00 | CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update

2018-08-02 08:00:00 | CymaBay to Report Second Quarter 2018 Financial Results on Thursday, August 9

2018-08-02 07:23:11 | New Strong Sell Stocks for August 2nd

2018-08-01 08:00:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics — New Research Emphasizes Economic Growth

2018-07-26 06:34:10 | New Strong Sell Stocks for July 26th

2018-07-11 08:06:12 | New Strong Sell Stocks for July 11th

2018-06-25 08:00:00 | CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes

2018-06-19 08:00:00 | CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018

2018-05-11 23:46:57 | Edited Transcript of CBAY earnings conference call or presentation 8-May-18 8:30pm GMT

2018-05-10 07:40:00 | Wired News – CymaBay Therapeutics Starts Phase-2b Clinical Trials of Seladelpar for Treatment of Patients with Non-Alcoholic Steatohepatitis

2018-05-08 16:01:00 | CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update

2018-05-08 08:00:00 | CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis

2018-05-01 08:00:00 | CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8

2018-04-20 08:25:00 | Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta, Hornbeck Offshore Services, and Sprouts Farmers Market — Future Expectations, Projections Moving into 2018

2018-04-18 08:26:40 | Analysts’ Ratings for Achaogen and Peers in April 2018

2018-04-17 08:02:26 | How Has CymaBay Therapeutics Performed Financially?

2018-04-17 08:02:26 | Exploring CymaBay’s Other Promising Product Candidates

2018-04-17 08:02:25 | What Analysts Recommend for CymaBay Therapeutics

2018-04-17 08:02:25 | Key Updates on CymaBay’s Lead Product Candidate